NEURACAP
Sector OutlookPublished · 22 pages · Free to read

Specialty Chemicals Sector Outlook — September 2026

A sector review of fourteen specialty chemicals companies: how the market prices a diversified core against two adjacencies, what separates the top of the valuation range from the bottom, and what buyers have paid for whole companies and carve-outs. For owners, boards and investors on capital allocation.

For information only. Not an appraisal or a fairness opinion.

What moved since: Specialty Chemicals M&A update, 14–28 September 2026

Key figures

Sector median EV/EBITDA
8.9x
CY2027E, rated names
Top-of-range multiple
17.7x
CY2027E, top three names
Bottom-of-range multiple
6.6x
CY2027E, bottom three names
Diversified core share
79%
of 14 approved companies

Read the report

NeuraCap

MATERIALS › MATERIALS › SPECIALTY CHEMICALS

Specialty Chemicals: Priced as Three Markets, Not One

How the market is currently reading fourteen specialty chemicals names, what separates the top of the range from the bottom, and what buyers have paid for whole companies and carve-outs.

September 2026 · Prepared by NeuraCap AI · Confidential

Market data as of 2026-09-28 · primary valuation basis EV / EBITDA (CY2027E)

Specialty Chemicals Coverage | September 2026 | Confidential | Not investment advice

1

1 / 22

Executive summary

Specialty Chemicals prices as three markets rather than one: a diversified core near 8.4x, an oilfield-linked adjacency near 12.4x, and a top group near 17.7x, against a sector median of 8.9x. The premium sits with the faster-growing half of the set at 14.0x versus 8.2x, and two pending deals — Solstice Advanced Materials Inc for Element Solutions Inc at $16.4B, and Olin Corporation for Huntsman Corporation at $6.8B — show operating buyers paying for capability. Growth, margin and scale travel together at the top of this set.

Key findings

  • Top of range trades at 17.7x vs 6.6x at the bottom, sector median 8.9x
  • Faster-growing names command 14.0x vs 8.2x for slower peers
  • 79% of names sit in the diversified core, priced at a median 8.4x
  • Two pending deals, $16.4B and $6.8B, show buyers paying for capability

What each page shows

The analyst’s walkthrough of the deck, page by page.

  1. 01
    MATERIALS › MATERIALS › SPECIALTY CHEMICALS

    Specialty Chemicals: Priced as Three Markets, Not One

    Cover slide introducing the sector outlook and its central framing that Specialty Chemicals prices as three distinct markets.

    We open with the finding that carries through this deck: Specialty Chemicals reads as one label but prices as three separate markets. Everything that follows builds the evidence behind that framing, so it's worth carrying into every page.

    Everything on this page

    MATERIALS › MATERIALS › SPECIALTY CHEMICALS Specialty Chemicals: Priced as Three Markets, Not One How the market is currently reading fourteen specialty chemicals names, what separates the top of the range from the bottom, and what buyers have paid for whole companies and carve-outs. September 2026 · Prepared by NeuraCap AI · Confidential Market data as of 2026-09-28 · primary valuation basis EV / EBITDA (CY2027E) Specialty Chemicals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 1

  2. 02
    CONTENTS

    What This Report Covers

    This page lists the five sections and appendix that structure the report.

    We've built this report in five sections plus an appendix, starting with the bottom line and moving through the landscape, valuation, precedent transactions and strategic implications. We put the bottom line first by design — a reader who stops after section one still leaves with the full story. That structure lets us front-load the conclusion and use the rest of the deck to show our work.

    Everything on this page

    CONTENTS What This Report Covers 01 The Bottom Line Start Here: One Sector Label, Several Markets 02 The Landscape The Diversified Core and Its Two Adjacencies 03 Valuation & Situations The Range Runs Wide on the Same Forward Lens 04 Precedent Transactions Buyers Have Stayed Active at the Top End of Value 05 Strategic Implications Where the Next Dollar of Capital Earns A Higher Multiple 06 Appendix Comparables Detail, Methodology, Sources and Assumptions Specialty Chemicals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 2

  3. 03
    01 · THE BOTTOM LINE

    Specialty Chemicals Prices as Three Markets: A Diversified Core, an Oilfield-Linked Adjacency and a Small Premium Group

    This page summarizes the bottom line: Specialty Chemicals prices as three markets — a diversified core, an oilfield-linked adjacency and a small premium group.

    We see three of the fourteen companies at the top of the range trading at 17.7x CY2027E EV/EBITDA, three at the bottom near 6.6x, and the sector median sitting at 8.9x — the spread is where the commercial question lives. The premium sits with the faster-growing half of the set: names growing revenue above the covered median carry a median multiple of 14.0x against 8.2x for the slower half. Four in five names, 79% of the set, sit in the diversified core at a median of 8.4x, while the oilfield-linked adjacency prices above it at 12.4x on a small base of names. Two pending deals of scale — Solstice Advanced Materials Inc for Element Solutions Inc at $16.4B, and Olin Corporation for Huntsman Corporation at $6.8B — show operating buyers paying up for capability, so the pricing story and the deal record point the same direction.

    Everything on this page

    01 · THE BOTTOM LINE Specialty Chemicals Prices as Three Markets: A Diversified Core, an Oilfield-Linked Adjacency and a Small Premium Group The full story on one page · figures on EV / EBITDA (CY2027E), market data as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / EBITDA on CY2027E consensus (12 of 14 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Qualitative characterisations are NeuraCap views. Specialty Chemicals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 3 1 The Top of the Range Is A Three-Name Group, and the Gap to the Bottom Is Wide Three of the 14 companies on the page sit at 17.7x on CY2027E EV / EBITDA, alongside three at the bottom at 6.6x, with the middle of the range at 8.9x. Same lens, same period, one sector label — the spread is where the commercial question lives. 2 The Premium Sits with the Faster-Growing Half of the Set The six names growing revenue above 8% carry a middle multiple of 14.0x, against 8.2x for the six below that line. A forward lens already credits the forecast, so a premium that survives it points to earnings the market expects to hold rather than one good year. 3 Four in Five Names Sit in the Diversified Core, and the Adjacency Prices Above It 11 of the 14 companies, 79% of the set, are diversified specialty chemicals formulators, and the middle of that group sits at 8.4x. The two oilfield-linked names sit at 12.4x — a base of only two companies, so read it as direction rather than a rule. 4 Operating Buyers Are Lining up with Specification-Led Targets, Which Reads as A Capability Fit The transaction record carries two pending deals of scale: Solstice Advanced Materials Inc for Element Solutions Inc at $16.4B, and Olin Corporation for Huntsman Corporation at $6.8B. Both buyers are operating chemical companies, which reads as adding adjacent chemistries and registrations rather than a financial thesis. 8.9x Sector median EV/EBITDA CY2027E consensus · 12 rated of 14 companies 17.7x Premium end EV/EBITDA vs 6.6x at the discount end top quartile (n=3) against bottom quartile (n=3) on EV/EBITDA — the spread the report explains 41 Transactions with disclosed terms 134 recorded in this tier · 3 told as case studies, the full list in the appendix

  4. 04
    SECTION 02

    02

    Section divider introducing the market map of the diversified core and its two adjacencies.

    This section maps who sits where across the diversified core and its two adjacencies, and how each group prices. It sets up the landscape view that follows.

    Everything on this page

    SECTION 02 02 THE LANDSCAPE The Diversified Core and Its Two Adjacencies Who sits where, what each group sells and how each is priced. 02 of 06 Specialty Chemicals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 4

  5. 05
    02 · MARKET MAP

    Four in Five Names Formulate Across End Markets; The Adjacencies Hold the Rest

    This page groups the fourteen approved companies by business segment and shows the median EV/EBITDA for each group.

    We group all fourteen approved companies by business segment, and 79% of them sit in the diversified core that formulates across end markets. The remaining names split into the two adjacencies, each priced separately from the core. Seeing the split this way makes clear that a single sector multiple would blur three different businesses into one number.

    Everything on this page

    02 · MARKET MAP Four in Five Names Formulate Across End Markets; The Adjacencies Hold the Rest 14 approved companies grouped by business segment · median EV / EBITDA (CY2027E) per group · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Segment grouping follows the platform's classification; group medians on rated names only. "Why it matters" lines are NeuraCap views. Specialty Chemicals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 5 DIVERSIFIED SPECIALTY CHEMICALS 11 cos median 8.4x Ecolab (ECL) LyondellBasell (LYB) Eastman Chemical (EMN) NewMarket (NEU) Calumet (CLMT) Avient (AVNT) Minerals (MTX) WD-40 (WDFC) Innospec (IOSP) Stepan (SCL) Northern (NTIC) The weight of the set: formulators selling into construction, consumer, electronics and industrial applications, with mix running from specified-in chemistry to merchant tonnage. ADJACENT: OILFIELD EQUIPMENT AND FIELD SERVICES 2 cos median 12.4x Flotek Industries (FTK) TETRA Technologies (TTI) Chemistry and services tied to well activity, where end-market cycle timing is read separately from portfolio quality. ADJACENT: CHEMICAL HANDLING, DISPENSING AND APPLICATION EQUIPMENT 1 cos 10.3x · 1 rated Universal Display (OLED) One name with licensing and royalty economics, where the earnings are cash-like and capital intensity is light.

  6. 06
    02 · LANDSCAPE

    The Core Is Broad and Prices Below Both of Its Adjacencies

    This page presents segment-level medians showing the core prices below both adjacencies.

    The diversified core is the broadest group in this set, and its median EV/EBITDA of 8.4x sits below both adjacencies, including the oilfield-linked group at 12.4x. That gap tells us breadth alone doesn't earn the multiple — the adjacencies command a premium despite a smaller base of names. The read for any owner in the core is that scale has to be matched with the growth or margin profile the market is pricing in the adjacencies.

    Everything on this page

    02 · LANDSCAPE The Core Is Broad and Prices Below Both of Its Adjacencies Segment view of the approved universe · EV / EBITDA (CY2027E) medians on rated names · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. "What they do / why it matters" is a NeuraCap view. Full company-level detail in the appendix and companion tables. Specialty Chemicals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 6 Segment n Share of universe Median EV/EBITDA Names to know What they do — and why it matters Diversified specialty chemicals 11 79% 8.4x Ecolab Inc. (ECL) · LyondellBasell Industries N.V. (LYB) · +9 more The weight of the set. 11 of the 14 companies, 79% of the set, formulate across construction, consumer, electronics and industrial end markets, and the middle of the group sits at 8.4x on CY2027E EV / EBITDA. Mix inside the group runs from specified-in chemistry with long qualification cycles to substitutable volume priced off a raw material spread, and the names price far apart because of it. Adjacent: oilfield equipment and field services 2 14% 12.4x Flotek Industries, Inc. (FTK) · TETRA Technologies, Inc. (TTI) Two names tied to activity. Flotek Industries, Inc. (FTK) and TETRA Technologies, Inc. (TTI) supply chemistry and field services into well activity, and on those two names the middle sits at 12.4x. Concentration in one cyclical end market cuts both ways: it lifts pricing when activity is forecast up, and it is the first thing a buyer stress-tests. Adjacent: chemical handling, dispensing and application equipment 1 7% 10.3x n=1 Universal Display Corporation (OLED) One name, licensing economics. Universal Display Corporation (OLED) sits here on its own at 10.3x, with a patent estate and royalty streams on proprietary materials rather than a blending footprint. On a base of one company the figure is a marker, not a segment read — but it shows what the market pays for materials that are specified into a customer's process.

  7. 07
    SECTION 03

    03

    Section divider introducing the public market valuation range and what separates its top from its bottom.

    This section walks the valuation range end to end, from where the top of the range sits to where the bottom sits, and what the two ends share. It's the evidence behind the bottom line's framing.

    Everything on this page

    SECTION 03 03 VALUATION & SITUATIONS The Range Runs Wide on the Same Forward Lens Where the top and the bottom of the range sit, and what the two ends share. 03 of 06 Specialty Chemicals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 7

  8. 08
    03 · PUBLIC MARKET VALUATION

    Three Names Hold the Top of the Range, and Growth Is What They Share

    This page ranks all twelve rated companies by EV/EBITDA (CY2027E) against a sector median of 8.9x.

    Three names hold the top of the range in this set, well above the sector median of 8.9x, and growth is the attribute they share. The bottom of the range sits well below that median too, with a wide gap between the two ends on the same forward lens. That spread, on one consistent basis and one period, is the commercial question this report is built to answer.

    Everything on this page

    03 · PUBLIC MARKET VALUATION Three Names Hold the Top of the Range, and Growth Is What They Share EV / EBITDA (CY2027E) · all 12 rated companies, sorted descending · sector median 8.9x · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / EBITDA on CY2027E consensus (12 of 14 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Tier zones are NeuraCap groupings cut at the rated set's quartiles; every multiple quoted on this page is a median on the same EV / EBITDA (CY2027E) basis. Panel commentary is a NeuraCap view. Specialty Chemicals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 8 PREMIUM · median 17.7x CORE · median 8.9x DISCOUNT · median 6.6x Sector median 8.9x WHAT SEPARATES THE TWO ENDS The top three price at 17.7x. WD-40 Company (WDFC), Ecolab Inc. (ECL) and Flotek Industries, Inc. (FTK) sit at the top of the range at 17.7x on CY2027E EV / EBITDA. All three report revenue growth above the covered middle, and two of the three combine that with margins above the set's midpoint. The bottom three price at 6.6x. Eastman Chemical Company (EMN), Minerals Technologies Inc. (MTX) and LyondellBasell Industries N.V. (LYB) sit at the bottom of the range at 6.6x. Two of the three report growth below the covered middle, and the market appears to be reading more substitutable volume and feedstock spread exposure into this end of the set. A forward lens already credits growth. The lens is CY2027E EV / EBITDA, so the earnings recovery this group is forecast to deliver is already inside today's price. Fourteen companies sit on this page and 12 of them carry a forward estimate, which means a premium that survives the forward test is a statement about durability rather than about the next print.

  9. 09
    03 · VALUATION DRIVERS

    Growth Above the Covered Middle Is Where the Multiple Steps Up

    This page splits the rated set into faster- and slower-growth cohorts and shows the median multiple for each.

    The companies growing revenue above the covered median carry a median EV/EBITDA of 14.0x, while those below that line sit at 8.2x. Because this is a forward multiple, it already prices in expected growth — a premium that survives that lens signals growth the market expects to hold, not one strong year. That association, not causation, is what we read into the split, and it's the strongest driver we see in this set.

    Everything on this page

    03 · VALUATION DRIVERS Growth Above the Covered Middle Is Where the Multiple Steps Up Median EV / EBITDA (CY2027E) by revenue-growth cohort and by EBITDA-margin cohort (each split at its covered median) · rated names with estimates · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Cohort medians on rated names with the required estimates (faster n=6; slower n=6; higher-margin n=6; lower-margin n=6). Driver readings are NeuraCap views on the supplied data — association, not causation. Specialty Chemicals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 9 EV/EBITDA, median per cohort · growth split at 8% · EBITDA-margin split at 18% The Growth Line Is Where the Pricing Step Appears On the 12 names with a forward estimate, the six growing revenue above 8% carry a median 14.0x on CY2027E EV / EBITDA against 8.2x for the six below. Six names a side is a small base, so the step is a direction of travel rather than a formula — but it is the clearest split on the page. Margin on Its Own Shows a Smaller Step Split the same names at 18% EBITDA margin and the picture flattens: the group with margin above that line but growth below it prices close to the middle of the range. Margin is priced in this set, but on this evidence it travels with growth rather than standing in for it. Pass-Through Architecture Is What Holds Contribution The names that held contribution through the feedstock cycle did it with index-linked or contractual pass-through and value-in-use pricing, not with cost recovery arguments after the fact. Where pass-through lag is short and documented in the contract, a buyer will underwrite mid-cycle earnings closer to the reported number. Single-End-Market Exposure Is Read Name by Name Inside the oilfield-linked adjacency the two names sit far apart: Flotek Industries, Inc. (FTK) at 16.9x and TETRA Technologies, Inc. (TTI) at 8.0x on the same forward lens. On a base of two companies that suggests buyers are pricing activity exposure case by case rather than treating the adjacency as one block.

  10. 10
    03 · SITUATION MAP

    Four Situations in This Set: Where a Company Sits on Growth and Profitability Points to a Different Agenda

    This page maps companies into four situations by cutting EV/EBITDA against the 8.9x sector median and revenue growth against the 8% covered median.

    We cut this set two ways: EV/EBITDA against the sector median of 8.9x, and revenue growth against the covered median of 8%. That produces four situations, each pointing toward a different agenda for the company sitting in it. These are observations on where a company sits today, not a recommendation to buy or sell any position.

    Everything on this page

    03 · SITUATION MAP Four Situations in This Set: Where a Company Sits on Growth and Profitability Points to a Different Agenda Cut on EV / EBITDA vs the sector median (8.9x) (rows) and revenue growth vs the covered median (8%) (columns) · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Situation boundaries are the cohort's own medians (Directional, NeuraCap view). This page characterises situations; it does not recommend buying or selling any security. Specialty Chemicals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 10 Credited and Delivering Above-median multiple · above-median revenue growth 4 names Ecolab Inc. (ECL) · Calumet Inc. (CLMT) · WD-40 Company (WDFC) · +1 more The multiple already assumes execution; the agenda is defending what the market has credited. Premium Ahead of the Operating Case Above-median multiple · below-median revenue growth 2 names Universal Display Corporation (OLED) · Innospec Inc. (IOSP) The premium outruns the operating measure beneath it; the gap wants an answer before the market asks the question. Operating Case Ahead of the Price Below-median multiple · above-median revenue growth 2 names LyondellBasell Industries N.V. (LYB) · Stepan Co (SCL) The operating case runs ahead of the price — the re-rating conversation lives in this cell. Priced for What It Is Below-median multiple · below-median revenue growth 4 names Eastman Chemical Company (EMN) · Avient Corporation (AVNT) · Minerals Technologies Inc. (MTX) · +1 more Priced as what it is today; ownership, structure and capital-allocation questions dominate.

  11. 11
    03 · GROWTH VS PROFITABILITY

    Two of the 12 Names with a Forward Estimate Clear Both the Growth Bar and the Margin Bar, at the Top of the Range

    This page plots the companies with both a growth and a margin estimate against the covered medians of 8% growth and 18% margin.

    Of the names with both a growth and a margin estimate, only two clear both the 8% growth bar and the 18% margin bar, and both sit at the top of the range. FTK and OLED plot at the edge of this chart, outside the core cluster. Clearing both bars together is rare in this set, which is exactly why the names that do command the premium multiples we've seen through this section.

    Everything on this page

    03 · GROWTH VS PROFITABILITY Two of the 12 Names with a Forward Estimate Clear Both the Growth Bar and the Margin Bar, at the Top of the Range Revenue growth (CY2026E, x-axis) vs EBITDA margin (CY2027E, y-axis) · 12 companies with both estimates · cuts at the covered medians (8% growth, 18% margin) · median EV/EBITDA per quadrant · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Quadrant cuts are the covered set's medians. Quadrant medians on names with a meaningful EV/EBITDA (balanced n=2; margin-only n=4; growth-only n=4; neither n=2). FTK, OLED plotted at the chart edge. Specialty Chemicals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 11 0% 10% 20% 30% 40% 10% 20% 30% 40% MARGIN ONLY median 8.2x BALANCED median 19.2x NEITHER median 8.3x GROWTH ONLY median 9.3x OLED AVNT TTI MTX EMN IOSP SCL LYB ECL WDFC CLMT FTK x: revenue growth (CY2026E) · y: EBITDA margin (CY2027E) HOW TO READ THIS The horizontal split is revenue growth against the covered middle; the vertical split is EBITDA margin at 18%. Two names clear both bars — Ecolab Inc. (ECL) and WD-40 Company (WDFC) — and on those two companies the median is 19.2x. Four names clear growth only and sit near 9.3x, four clear margin only, and two clear neither. Each cell here is a handful of names, so read the cells as direction and test the mechanism in your own portfolio. Rule of 40 (revenue growth + EBITDA margin ≥ 40%): 2 of 12 names clear it (FTK, OLED).

  12. 12
    03 · THE AGENDA

    Growth, Margin and Scale Are the Three Attributes That Sit with the Names at the Top of the Range

    This page frames growth, margin and scale as the three attributes shared by the names at the top of the range, posed as questions for an owner or acquirer.

    Growth, margin and scale are the three attributes that travel together with the names at the top of this range. We frame these as questions an owner or acquirer needs to resolve, not as a scorecard to pass or fail. Resolving them is what determines whether a company's multiple has room to move toward the top of this set.

    Everything on this page

    03 · THE AGENDA Growth, Margin and Scale Are the Three Attributes That Sit with the Names at the Top of the Range NeuraCap view · framed as the questions an owner or acquirer should resolve · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All content on this page is Directional — NeuraCap advisory judgment grounded in the cohort data shown earlier. It does not constitute investment advice. Specialty Chemicals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 12 Put Formulation Spend Behind Specified-in Applications The pricing evidence favours chemistry that is written into a customer's process or product, where the qualification cycle creates switching cost once won. That argues for concentrating application development and technical service on the applications with the longest qualification path and the clearest value-in-use case. What changes the answer: Qualification pipeline converting to spec positions while contribution per pound holds. Harden Pass-Through Before the Next Feedstock Swing Index-linked and contractual pass-through mechanics are what let a business carry margin through a raw material move rather than arguing it back afterwards. Shortening the lag and widening contractual coverage changes the earnings a buyer is willing to treat as mid-cycle. What changes the answer: Contribution margin holding through a period when feedstock moves sharply. Decide Whether to Price or Prune the Commodity Tail Merchant, substitutable volume exposed to imported supply sits at the discount end of this set. The choice is to reprice it on service and dosing economics, or to move capital out of it toward lines with registrations and specification positions behind them. What changes the answer: A sub-scale line failing to earn its fixed-cost absorption across a full cycle. Test Build-Versus-Buy on Registrations and Specification Positions The transaction record shows operating buyers paying up for adjacent chemistries, registrations and qualified positions, and shows corporates selling non-core lines as carve-outs. Both sides of that flow are available to an owner weighing whether to qualify a new application or acquire one already specified. What changes the answer: A carve-out coming available in an application where your own qualification path is years long.

  13. 13
    SECTION 04

    04

    Section divider introducing what buyers have paid for whole companies and for carve-outs.

    This section turns to the transaction record — what acquirers have agreed to pay for whole companies and for carve-outs of single lines. It shows whether the pricing evidence in the public market lines up with what buyers are actually paying.

    Everything on this page

    SECTION 04 04 PRECEDENT TRANSACTIONS Buyers Have Stayed Active at the Top End of Value What acquirers paid for whole companies and for carve-outs of single lines. 04 of 06 Specialty Chemicals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 13

  14. 14
    04 · DEAL CASE STUDIES

    What Buyers Agreed to Pay for Whole Companies: Two Pending Deals of Scale Anchor the Record

    This page presents three case studies from the disclosed-terms transactions, anchored by two pending deals of scale.

    Two pending deals of scale anchor this record: Solstice Advanced Materials Inc's agreement to acquire Element Solutions Inc at $16.4B, and Olin Corporation's agreement to acquire Huntsman Corporation at $6.8B. Both buyers are operating chemical companies, which reads as a capability fit — adjacent chemistries and registrations — rather than a purely financial thesis. These three case studies sit inside a wider record of transactions with disclosed terms, with the full list available for anyone who wants to trace every deal.

    Everything on this page

    04 · DEAL CASE STUDIES What Buyers Agreed to Pay for Whole Companies: Two Pending Deals of Scale Anchor the Record 3 of 41 transactions with disclosed terms, told as case studies · multiples on LTM financials at announcement where disclosed · the complete list is in the appendix · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 175 precedent record(s) carry data-quality flags (carve out target recorded as parent; deal value unit unresolved; divestiture roles reassigned); figures are shown as recorded in the filing. 93 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. "Why the deal happened" is a NeuraCap read of the recorded evidence. Specialty Chemicals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 14 Jul-2026 $16.4B Solstice Advanced Materials Inc acquires Element Solutions Inc EV / LTM revenue 5.2x EV / LTM EBITDA 26.0x WHY THE DEAL HAPPENED Solstice Advanced Materials Inc makes advanced materials and Element Solutions Inc formulates specialty chemistry for electronics and industrial assembly. A transaction of this size reads as acquiring specification positions, registrations and qualified customer platforms that would otherwise take years of qualification cycles to build. HOW THE TARGET WAS VALUED Terms are recorded at $16.4B and 26.0x EV / EBITDA, pending as of July 2026. That earnings multiple sits well above the top of the public range on the forward lens, which is the kind of gap whole-company purchases of specified-in chemistry have carried in this record. Jun-2026 $6.8B Olin Corporation Olin Corporation's $6.8B move on Huntsman Corporation puts two plant-heavy producers together. EV / LTM revenue 1.2x EV / LTM EBITDA 29.4x WHY THE DEAL HAPPENED Both companies run capital-intensive chemistry with feedstock and energy cost position at the centre of competitiveness. The pairing reads as scale, feedstock position and fixed-cost absorption rather than entry into new end markets. HOW THE TARGET WAS VALUED Recorded at $6.8B, 1.2x revenue and 29.4x EBITDA, pending as of June 2026. A low revenue multiple sitting alongside a high earnings multiple is the signature of a trough period, and it is exactly the case both sides argue toward mid-cycle earnings to normalise. Jun-2022 $123M OneWater Marine Inc. acquires Ocean Bio-Chem, Inc. EV / LTM revenue 1.9x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED OneWater Marine Inc. sells and services boats; Ocean Bio-Chem, Inc. formulates branded marine care chemistry. The purchase reads as putting a consumable product line behind an installed customer base and dealer network. HOW THE TARGET WAS VALUED Recorded at $123M and 1.9x revenue, announced June 2022. Revenue multiples at that level sit with branded consumable chemistry sold through a channel, and in this sector they are read alongside contribution margin rather than on their own.

  15. 15
    SECTION 05

    05

    Section divider introducing where the next dollar of capital earns a higher multiple.

    This section turns the pricing and deal evidence into operating implications — where the next dollar of capital earns a higher multiple in this set. It's the strategic read that follows from everything shown so far.

    Everything on this page

    SECTION 05 05 STRATEGIC IMPLICATIONS Where the Next Dollar of Capital Earns A Higher Multiple The operating moves this pricing evidence points to. 05 of 06 Specialty Chemicals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 15

  16. 16
    05 · STRATEGIC IMPLICATIONS

    Where the Higher Multiples Sit in This Set, and the Capital Choices That Go with Them

    This page sets out the capital allocation choices that follow from where the higher multiples sit in this set.

    The higher multiples in this set sit with growth that holds and margins that hold alongside it, and that pairing points to specific capital choices. Owners can weigh where to put technical service and capacity; boards can weigh building a qualified position versus acquiring one that's already qualified, given the pending deals in this record. These are observations on where value sits, not a recommendation to buy or sell any security.

    Everything on this page

    05 · STRATEGIC IMPLICATIONS Where the Higher Multiples Sit in This Set, and the Capital Choices That Go with Them NeuraCap view · the questions this data puts on the table for the next twelve months Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. This page is Directional — NeuraCap views drawn from the analysis in this report. Observations, not recommendations. Specialty Chemicals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 16 FOR OWNERS Mix Travels with the Multiple The top of the range in this peer set pairs growth above the covered middle with margins that hold, and the bottom carries more substitutable volume. The practical move is at the portfolio level: which applications get technical service and capacity, how price is defended on value-in-use, and which lines are asked to earn their fixed cost. FOR BOARDS Build-Versus-Buy Is Live at These Levels Two pending deals of scale and a steady run of carve-outs in the record show operating buyers paying for chemistry already specified in, and corporates pruning tails. That frames the capital allocation question plainly: qualify the next application yourself, or acquire a position that is already qualified. FOR BUYERS AND INVESTORS The Earnings Bridge Is Where the Work Sits Pricing in this sector is negotiated off adjusted EBITDA both sides argue toward mid-cycle, so the diligence that moves value is on pass-through and lag, inventory accounting through the period, turnaround timing inside the window, and environmental reserves that travel with the sites.

  17. 17
    SECTION 06

    06

    Section divider introducing the full comparables universe, methodology and sources for the report.

    This final section carries the comparables detail behind every figure shown in the body, the valuation basis used throughout, and where each disclosure sits. It's the reference material for anyone who wants to trace a number back to its source.

    Everything on this page

    SECTION 06 06 APPENDIX The Full Universe, Methodology and Sources Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. 06 of 06 Specialty Chemicals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 17

  18. 18
    06 · PUBLIC COMPARABLES (1 OF 1)

    Public Comparables on EV / EBITDA (CY2027E), Grouped by Valuation Tier

    This appendix page lists all twelve rated companies and their EV/EBITDA (CY2027E), grouped by valuation tier against the 8.9x sector median.

    All twelve rated companies appear in this table, grouped into tiers above and below the 8.9x sector median, with two names carrying no eligible multiple. Every ticker links back to its underlying source, so any figure in this deck can be traced to where it came from. This is the full rated universe behind every chart in the body of the report.

    Everything on this page

    06 · PUBLIC COMPARABLES (1 OF 1) Public Comparables on EV / EBITDA (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/EBITDA above the sector median (8.9x); amber marks below · 12 rated companies; 2 not rated (no eligible EV/EBITDA) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 12 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Names without an eligible multiple are listed in the companion workbook. Specialty Chemicals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 18 Company Ticker Segment EV EV/EBITDA (CY2027E) Rev growth EBITDA margin Rule of 40 PREMIUM — ≥12.5x · median 17.7x · 3 companies WD-40 Company WDFC Diversified specialty chemicals $2.7B 20.8x 12% 18% 24 Ecolab Inc. ECL Diversified specialty chemicals $87.4B 17.7x 11% 26% 34 Flotek Industries, Inc. FTK Adjacent: oilfield equipment and field services $1.1B 16.9x 50% 16% 29 CORE — 7.5x–12.5x · median 8.9x · 6 companies Calumet Inc. CLMT Diversified specialty chemicals $7.1B 11.0x 19% 14% 9 Universal Display Corporation OLED Adjacent: chemical handling, dispensing and… $3.1B 10.3x -3% 45% 53 Innospec Inc. IOSP Diversified specialty chemicals $2.2B 9.3x 7% 12% 18 Avient Corporation AVNT Diversified specialty chemicals $5.3B 8.4x 5% 18% 21 TETRA Technologies, Inc. TTI Adjacent: oilfield equipment and field services $1.0B 8.0x 5% 18% 25 Stepan Co SCL Diversified specialty chemicals $2.0B 7.6x 9% 10% 16 DISCOUNT — <7.5x · median 6.6x · 3 companies Eastman Chemical Company EMN Diversified specialty chemicals $12.3B 7.3x 6% 18% 20 Minerals Technologies Inc. MTX Diversified specialty chemicals $2.8B 6.6x 5% 18% 23 LyondellBasell Industries N.V. LYB Diversified specialty chemicals $28.9B 6.5x 10% 14% 9

  19. 19
    06 · PRECEDENT TRANSACTIONS (1 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    This appendix page lists the first half of the precedent transactions with disclosed terms, sorted newest first.

    This table carries a first set of the transactions with disclosed terms in this tier, sorted newest first, out of a larger recorded total. Deal multiples are LTM at announcement and sit on a different basis than the CY2027E public multiples used elsewhere in this report, so we don't claim a spread between the two. Every deal value links to its underlying filing for anyone who wants to verify a specific transaction.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (1 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 41 transactions with disclosed terms in this tier (134 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 175 precedent record(s) carry data-quality flags (carve out target recorded as parent; deal value unit unresolved; divestiture roles reassigned); figures are shown as recorded in the filing. 93 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. 18 of 41 transactions shown; the rest are in the companion workbook. Specialty Chemicals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 19 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Jul-2026 Solstice Advanced Materials Inc → Element Solutions Inc $16.4B 5.2x 26.0x Solstice Advanced Materials Inc agreed in July 2026 to acquire Element Solutions Inc, recorded at 5.2x revenue and pending. Values are shown as recorded in the filing. Jun-2026 Olin Corporation → Huntsman Corporation $6.8B 1.2x 29.4x Olin Corporation's June 2026 agreement for Huntsman Corporation is recorded at 1.2x revenue and pending. Revenue multiples at that level sit with plant-heavy chemistry priced off a spread rather than on value-in-use. Dec-2025 Stonepeak → Castrol $10.0B n/a n/a Stonepeak's December 2025 agreement for Castrol is recorded at $10.0B and pending. Branded lubricants offer steady cash conversion, which is the profile long-hold and family capital has competed for in this sector. Nov-2025 n/a → Church & Dwight Co., Inc. n/a n/a 15.5x The November 2025 transaction recorded for Church & Dwight Co., Inc. carries 15.5x EBITDA. That level sits at the branded consumer-maintenance end, where earnings are cash-like and sustaining capital is light. Aug-2025 Hostess Brands → Fortress fire-retardant business n/a n/a 16.0x Hostess Brands' August 2025 transaction for the Fortress fire-retardant business is recorded at 16.0x EBITDA. Carve-outs of single application lines are a recurring shape here, and the registrations and dossiers travel with the assets. Jun-2025 Korea Water Resources Corporation → Water Solutions business of LG Chem, Ltd n/a 6.3x n/a Korea Water Resources Corporation's June 2025 transaction for the Water Solutions business of LG Chem, Ltd is recorded at 6.3x revenue. A corporate pruning a non-core line to an end-market operator is a recurring seller behaviour in this sector. Oct-2024 Nxu, Inc. → Verde Bioresins, Inc. $307M n/a n/a Nxu, Inc.'s October 2024 transaction for Verde Bioresins, Inc. is recorded at $307M. Values at this size mark the lower end of the record, where single-chemistry platforms and unproven application pipelines change hands. Nov-2022 Standard Industries Holdings Inc. → W.R. Grace & Co. n/a 3.6x 16.4x Standard Industries Holdings Inc.'s November 2022 transaction for W.R. Grace & Co. is recorded at 3.6x revenue and 16.4x EBITDA, with status recorded as terminated. It marks what a catalysts and materials platform was underwritten at in that window. Jun-2022 OneWater Marine Inc. → Ocean Bio-Chem, Inc. $123M 1.9x n/a OneWater Marine Inc.'s June 2022 purchase of Ocean Bio-Chem, Inc. is recorded at $123M. A distribution owner buying a consumable chemistry brand to pull product through its own channel is a recurring shape in this record.

  20. 20
    06 · PRECEDENT TRANSACTIONS (2 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    This appendix page continues the precedent transaction list, completing the disclosed-terms set shown newest first.

    This page completes the transaction list begun on the previous page, carrying the remaining names from the disclosed-terms transactions. The same basis applies throughout — LTM multiples at announcement, linked to the filing behind each one. Together the two pages give a full, traceable record of what buyers have agreed to pay across this set.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (2 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 41 transactions with disclosed terms in this tier (134 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 175 precedent record(s) carry data-quality flags (carve out target recorded as parent; deal value unit unresolved; divestiture roles reassigned); figures are shown as recorded in the filing. 93 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. 18 of 41 transactions shown; the rest are in the companion workbook. Specialty Chemicals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 20 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Dec-2021 Consortium (including Giant Investment (HK) Limited) → Delf (UK) Ltd. n/a 6.1x 13.0x Oct-2021 Ecolab Inc. → Purolite Corporation n/a n/a 23.0x Value shown as recorded in the filing; deal value unit unresolved, party direction corrected. Aug-2021 Lanxess AG → International Flavors & Fragrances Inc. (IFF)—Microbial Control business n/a n/a 13.0x Value shown as recorded in the filing; deal value unit unresolved. Mar-2021 Cerberus Capital Management, L.P. / Koch Minerals & Trading, LLC → PQ Group Holdings Inc.’s PQ Performance’s Chemicals Business n/a n/a 7.7x Feb-2021 Bain Capital Private Equity; Cinven → Lonza Group AG—Specialty Ingredients business n/a n/a 13.0x Value shown as recorded in the filing; deal value unit unresolved. Apr-2020 EQT → Schülke & Mayr GmbH n/a n/a 13.3x Value shown as recorded in the filing; deal value unit unresolved. Aug-2019 Undisclosed buyer → Koppers Holdings Inc. $1.6B 0.9x n/a Value shown as recorded in the filing; deal value unit unresolved, divestiture roles reassigned. Nov-2018 Univar Inc. → Nexeo Solutions, Inc. n/a n/a 9.6x Jul-2018 AptarGroup, Inc. → CSP Technologies S.à r.l. n/a n/a 13.0x Value shown as recorded in the filing; deal value unit unresolved.

  21. 21
    06 · METHODOLOGY

    Sources, Assumptions and Data Quality

    This appendix page explains the sources, assumptions and data-quality treatment behind the report.

    This page sets out how the figures in this report were built, what was excluded from the comparable set, and where each underlying disclosure sits. Every figure links to the record it came from, and where a link isn't available, the appendix names the source and the basis used. That transparency is what lets anyone trace a number in this deck back to its filing or estimate.

    Everything on this page

    06 · METHODOLOGY Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. Specialty Chemicals Coverage | September 2026 | Confidential | Not investment advice 21 VALUATION BASIS Primary valuation basis: EV / EBITDA on CY2027E consensus (12 of 14 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / EBITDA on CY2027E is the lead convention: it is the sector-appropriate prior for Specialty Chemicals and it clears the coverage gate with 12 of 14 companies (86%). EV / Revenue, P / E are carried as a cross-check. The set earns: 12 of the 12 companies with a reported forward EBITDA carry a meaningful one, so the profit multiple leads and a revenue multiple would understate what the market is pricing. DATA QUALITY & EXCLUSIONS 9 records were excluded or quarantined by the platform's validation gates (unit errors, implausible ratios, ineligible securities and classification failures); the full ledger ships in the companion tables and never feeds a statistic in this report. DEFINITIVE VS DIRECTIONAL Definitive content is disclosed or consensus data passed through stated arithmetic. Directional content — tier boundaries, situation cuts, "why it matters" commentary, the agenda pages — is NeuraCap analyst judgment and is labeled as such where it appears. WHAT THIS REPORT IS NOT This report characterises a sector. It does not recommend buying, selling or holding any security, and no statement in it should be read as investment advice or a price target. WHERE THE DATA LIVES 653 registered source documents stand behind the figures in this report. Metric hyperlinks throughout the deck open the specific filing or data record; by publisher: sec.gov (652) · home.treasury.gov (1). The companion workbook beside this deck carries the complete source index.

  22. 22

    On the 12 Names with a Forward Estimate, the Premium Sits with Growth That Holds.

    Closing slide restating that among the names with a forward estimate, the premium sits with growth that holds.

    On the twelve names with a forward estimate, the premium sits with growth that holds. That's the single takeaway worth carrying out of this room. The companion tables carry the full universe for anyone who wants to trace the detail behind it.

    Everything on this page

    On the 12 Names with a Forward Estimate, the Premium Sits with Growth That Holds. NeuraCap AI — Specialty Chemicals Coverage September 2026 · Prepared by NeuraCap AI · Confidential Specialty Chemicals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 22

Sources and methodology

This report covers Specialty Chemicals (Materials › Materials › Specialty Chemicals) with market data and consensus estimates as of September 28, 2026. The company universe is the 14 listed companies whose core business is Specialty Chemicals according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Avient Corporation (AVNT), Calumet Inc. (CLMT), Ecolab Inc. (ECL), Eastman Chemical Company (EMN), Flotek Industries, Inc. (FTK), Innospec Inc. (IOSP), LyondellBasell Industries N.V. (LYB), Minerals Technologies Inc. (MTX), NewMarket Corporation (NEU), Northern Technologies International Corporation (NTIC), Universal Display Corporation (OLED), Stepan Co (SCL), TETRA Technologies, Inc. (TTI), WD-40 Company (WDFC). The market map groups them by business vertical — Diversified specialty chemicals: 11 companies (ECL, LYB, EMN, NEU, CLMT, AVNT, MTX, WDFC, IOSP, SCL, NTIC); Adjacent: oilfield equipment and field services: 2 companies (FTK, TTI); Adjacent: chemical handling, dispensing and application equipment: 1 company (OLED). 12 of the 14 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

Scope and company universe

This report covers Specialty Chemicals (Materials › Materials › Specialty Chemicals) with market data and consensus estimates as of September 28, 2026. The company universe is the 14 listed companies whose core business is Specialty Chemicals according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Avient Corporation (AVNT), Calumet Inc. (CLMT), Ecolab Inc. (ECL), Eastman Chemical Company (EMN), Flotek Industries, Inc. (FTK), Innospec Inc. (IOSP), LyondellBasell Industries N.V. (LYB), Minerals Technologies Inc. (MTX), NewMarket Corporation (NEU), Northern Technologies International Corporation (NTIC), Universal Display Corporation (OLED), Stepan Co (SCL), TETRA Technologies, Inc. (TTI), WD-40 Company (WDFC). The market map groups them by business vertical — Diversified specialty chemicals: 11 companies (ECL, LYB, EMN, NEU, CLMT, AVNT, MTX, WDFC, IOSP, SCL, NTIC); Adjacent: oilfield equipment and field services: 2 companies (FTK, TTI); Adjacent: chemical handling, dispensing and application equipment: 1 company (OLED). 12 of the 14 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

What was excluded and why

9 records failed a validation gate and never feed a statistic in this report (1 excluded from universe; 8 excluded from aggregate). Each exclusion, with its reason: KWR — The ticker KWR carries a preferred, warrant or unit suffix and the security name gives no sign of an operating company (effect: excluded from universe) · CLMT — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CLMT — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CLMT — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · LYB — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · MTX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · NEU — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · NEU — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · NTIC — Non-positive EPS; P/E is n/m (effect: excluded from aggregate)

Primary valuation basis and how it was chosen

Primary valuation basis: EV / EBITDA on CY2027E consensus (12 of 14 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / EBITDA on CY2027E is the lead convention: it is the sector-appropriate prior for Specialty Chemicals and it clears the coverage gate with 12 of 14 companies (86%). EV / Revenue, P / E are carried as a cross-check. The set earns: 12 of the 12 companies with a reported forward EBITDA carry a meaningful one, so the profit multiple leads and a revenue multiple would understate what the market is pricing. The basis is selected in two steps: the industry's customary valuation conventions set the order of preference, and each convention is then tested for coverage — the share of companies with a valid, plausibility-checked multiple on the chosen period. A convention is used only when enough companies carry it; the best-covered convention is used, and disclosed, when none clears the threshold. Coverage measured for this report — EV / EBITDA: 12 of 14 companies; EV / rEVenue: 12 of 14 companies; P/E: 12 of 14 companies.

How the multiples and statistics are computed

Enterprise value (EV) is market capitalisation at the as-of date plus total debt minus cash and equivalents from the latest reported balance sheet, reconciled against the platform's stored value and disclosed where the two differ. Forward multiples divide EV (or the share price for P/E) by the consensus estimate for the stated calendar period; trailing multiples use the last twelve months of reported figures from SEC filings. A multiple with a negative or immaterial denominator is treated as not meaningful and excluded from every statistic. Cohort statistics are medians and quartiles over the rated set only; a group median with fewer than three observations is shown as the single company's figure and labelled as such. Valuation tiers cut the rated set at its quartiles (tiers cut at the rated set's quartiles: Premium ≥12.5x, Core 7.5x–12.5x, Discount <7.5x — NeuraCap groupings). Revenue growth compares consecutive calendar-year consensus revenue; EBITDA margin divides consensus EBITDA by consensus revenue for the same period. Figures shown in this report and the calculation behind each: 8.9x = median(ev_ebitda CY2027E) (12 rated companies) · 17.7x = median(ev_ebitda CY2027E) within Premium tier (n=3) · 8.9x = median(ev_ebitda CY2027E) within Core tier (n=6) · 6.6x = median(ev_ebitda CY2027E) within Discount tier (n=3) · 14.0x = median(ev_ebitda CY2027E) | growth ≥ 8% (n=6) · 8.2x = median(ev_ebitda CY2027E) | growth < 8% (n=6) · 9.4x = median(ev_ebitda CY2027E) | EBITDA margin ≥ 18% (n=6) · 8.4x = median(ev_ebitda CY2027E) | EBITDA margin < 18% (n=6) · 24% = median Rule of 40 score (revenue growth + EBITDA margin) (n=12) · 19.2x = median(ev_ebitda CY2027E) within balanced quadrant (n=2) · 8.2x = median(ev_ebitda CY2027E) within marginOnly quadrant (n=4) · 9.3x = median(ev_ebitda CY2027E) within growthOnly quadrant (n=4) · 8.3x = median(ev_ebitda CY2027E) within neither quadrant (n=2)

Precedent transactions: what is in the record and why

The precedent record holds the M&A transactions in Specialty Chemicals recorded from SEC filings (8-K announcements and the documents they reference), newest first, with each value and multiple linked to the exact passage in the filing that states it. 134 transactions were recorded for this industry; 41 are shown. 93 recorded transactions with neither a disclosed value nor a multiple are omitted because they say nothing about price; they remain in the companion workbook. Deal multiples are enterprise value over the target's last-twelve-month revenue or EBITDA at announcement, as disclosed; they are not restated to the public basis and no spread to the public multiples is claimed. Before a transaction reaches the record it passes a screen for mirrored or duplicate filings of the same deal, for divestitures where the filer is the seller rather than the buyer, for carve-outs recorded under the parent's name, and for values whose citation describes something other than the price paid (a debt raise, a termination fee); such records are corrected or excluded and the correction is noted. Data-quality notes on this record: 62 × deal value unit unresolved; 83 × no evidence record; 4 × duplicate precedent id; 1 × self transaction; 2 × duplicate filings collapsed; 1 × party direction corrected; 21 × divestiture roles reassigned; 1 × carve out target recorded as parent. Case studies lead with the 3 richest stories — disclosed value, a readable multiple, newest first.

Sources

Company financials and transaction terms come from the companies' own SEC filings on EDGAR (10-K, 10-Q and 8-K documents), linked from each figure in the report. Forward figures are analyst consensus estimates for the calendar periods shown. Share prices and market capitalisations are market data as of September 28, 2026. Treasury yields are published by the U.S. Department of the Treasury. 657 source documents stand behind this report; by publisher domain: sec.gov, home.treasury.gov (1). Every figure on every page is traceable to one of these records; nothing in the report is derived from outside data.

Interpretation and important notice

Tier labels, situation maps, the agenda and the implications pages are NeuraCap analytical views drawn from the recorded evidence and are labelled as such. The report is informational: it is not investment advice, not a recommendation to buy or sell any security, not an opinion of value and not an offer of any kind. Readers should perform their own diligence before acting on anything described here.

Sources linked in the report

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

Want this analysis for a company in Specialty Chemicals?

Company valuation reports run the same method against a single business — public or private.